Citations

Clear

2303 citation(s) found for "Yu, Edward".

Genomic and clinical characterization of stromal infiltration markers in prostate cancer
Mahal, Brandon A. , Alshalalfa, Mohammed , Zhao, Shuang G. , Beltran, Himisha , Chen, William S. , Chipidza, Fallon , Karnes, R. Jeffrey , Ku, Sheng‐Yu , Muralidhar, Vinayak , Schaeffer, Edward M. , Spratt, Daniel E. , Feng, Felix Y. , Nguyen, Paul L. , Spratt, Daniel E , Zhao, Shuang G , Davicioni, Elai , Lotan, Tamara Levin , Rebbeck, Timothy R.

Mayo Clinic

Cancer | January 6, 2020 | Volume: 126 | Issue: 7 | Pages: 1407-1412

10.1002/cncr.32688 | PMID 31905251 Get It

BackgroundThe progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer.MethodsGenome‐wide expression profiles of formalin‐fixed, paraffin‐embedded radical prostatectomy samples were evaluated from a prospective registry cohort (n = 5239) and 3 retrospective institutional cohorts (n = 1135). Two independent stromal gene expression signatures implied stromal infiltration. Cox proportional hazards regression defined the association between stromal infiltration expression and metastasis‐free survival (MFS).ResultsStromal expression scores were correlated with stromal signature genes and with other key stromal markers (CAV1, VIM, and TAGLN), basal activity, and CD3 and CD4 immune biomarkers (r > 0.5 for all). The top decile of stromal expression was associated with high genomic risk scores (Decipher ≥ 0.6) , high Cancer of the Prostate Risk Assessment–Postsurgical scores, Gleason 9 to 10 disease, and a higher risk for metastasis (hazard ratio, 2.35; 95% CI, 1.37‐4.02; P = .001). A higher stromal infiltration score was also associated with decreased expression of DNA repair genes and higher radiation sensitivity genomic scores. Postoperative radiation therapy (RT) was associated with an MFS benefit for patients with high stromal scores, but not for patients with low stromal scores (Pinteraction = .02).ConclusionsExpression of stromal infiltration markers is correlated with prostate cancer aggressiveness/progression and may be predictive of a response to RT. Stromal infiltration markers should be studied and considered for incorporation into clinical prognostication and decision making.
Analysis of Pneumocystis carinii Introns
Thomas, Charles F., Leof, Edward B. , Limper, Andrew H.

Mayo Clinic

Infection and Immunity | December 31, 2019 | Volume: 67 | Issue: 11 | Pages: 6157-6160

10.1128/iai.67.11.6157-6160.1999 | PMID 10531280 Get It

ABSTRACT Pneumocystis carinii is an ascomycete phylogenetically related to Schizosaccharomyces pombe . Little is known about gene regulation in P. carinii . The removal of introns from pre-mRNA requires spliceosomal recognition of the intron-exon boundary. In S. pombe and higher eukaryotes, this boundary and a branch site within the intron are conserved. We recently demonstrated that P. carinii cdc2 cDNA can complement S. pombe containing conditional mutations of cdc2 , an essential gene involved in cell cycle regulation. We next tested whether P. carinii genomic cdc2 (with six introns) could also complement S. pombe cdc2 mutants and found genomic sequences incapable of this activity. Reverse transcriptase PCR confirmed the inability of the S. pombe cdc2 mutants to splice the P. carinii genomic cdc2 . Analysis of 83 introns from 19 P. carinii protein-encoding genes demonstrated that the sequence GTWWDW functions as a donor consensus in P. carinii , whereas YAG serves as an acceptor consensus. These sequences are similar in S. pombe ; however, a branch site sequence was not found in the P. carinii genes studied.
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, Jun, Jermusyk, Ashley , Wu, Lang , Hoskins, Jason W. , Collins, Irene , Mocci, Evelina , Song, Lei , Chung, Charles C., Xiao, Wenming , Andreotti, Gabriella , Arslan, Alan A. , Babić, Ana , Berndt, Sonja, Borgida, Ayelet , Bracci, Paige M. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Childs, Erica J., Du, Mengmeng , Fuchs, Charles S. , Gallinger, Steven , Gaziano, J. Michael, Giovannucci, Edward L. , Goodman, Gary E. , Goodman, Phyllis J. , Haiman, Christopher, Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Holly, Elizabeth A., Klein, Eric A. , Kogevinas, Manolis, Kurtz, Robert J., Ng, Kimmie , Obazee, Ofure , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Sieri, Sabina , Tjønneland, Anne , Thornquist, Mark, Trichopoulou, Antonia , Visvanathan, Kala , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yuan, Chen , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Brown, Kevin M. , Jacobs, Eric J. , Li, Donghui , Yu, Kai , Wolpin, Brian M. , Chatterjee, Nilanjan , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Arslan, Alan A , Tjønneland, Anne , Wactawski-Wende, Jean , Visvanathan, Kala , Klein, Eric A , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Zhong, Jun , Yuan, Chen , Hoskins, Jason W , Zhang, Mingfeng , Zhang, Tongwu , Albanes, Demetrius , Bamlet, William R. , Freeman, Laura E. Beane , Brais, Lauren K , Canzian, Federico , Cotterchio, Michelle , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Marchand, Loı̈c Le , Malats, Núria , Männistö, Satu , Milne, Roger L. , Neale, Rachel Ε. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Van Den Eeden, Stephen K , White, Emily , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Shu, Xiao‐Ou , Chanock, Stephen Jacob , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Kraft, Peter , Zheng, Wei , Ámundadóttir, Laufey T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 31, 2019 | Volume: 112 | Issue: 10 | Pages: 1003-1012

10.1093/jnci/djz246 | PMID 31917448 Get It

Abstract Background Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. Methods To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). Results We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate < .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. Conclusions By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.
Impact of pre-admission vitamin D supplementation on mortality in septic patients
Finn, Ryan M. , Kule, Amy, Young, Katie, Rech, Megan A.

Mayo Clinic

Journal of the Intensive Care Society | December 19, 2019 | Volume: 24 | Issue: 3_suppl | Pages: 6-8

10.1177/1751143719896560 | PMID 37928094 Get It

Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-β
Yin, Xueqian , Choudhury, Malay , Kang, Jeong Han , Schaefbauer, Kyle, Jung, Mi-Yeon, Andrianifahanana, Mahefatiana, Hernandez, Danielle M. , Leof, Edward B. , Schaefbauer, Kyle J.

Mayo Clinic

Science Signaling | December 17, 2019 | Volume: 12 | Issue: 612 | Pages: No page available

10.1126/scisignal.aax4067 | PMID 31848318 Get It

TGF-β–dependent metabolic dysregulation contributes to lung fibrosis.
Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD‐L1 into extracellular vesicles
Kang, Jeong Han , Choudhury, Malay , Leof, Edward B. , Jung, Mi-Yeon, Jung, Mi‐Yeon

Mayo Clinic

The FASEB Journal | December 13, 2019 | Volume: 34 | Issue: 2 | Pages: 2213-2226

10.1096/fj.201902354r | PMID 31907984 Get It

Abstract Transforming growth factor‐beta (TGFβ) is an enigmatic protein with various roles in healthy tissue homeostasis/development as well as the development or progression of cancer, wound healing, fibrotic disorders, and immune modulation, to name a few. As TGFβ is causal to various fibroproliferative disorders featuring localized or systemic tissue/organ fibrosis as well as the activated stroma observed in various malignancies, characterizing the pathways and players mediating its action is fundamental. In the current study, we found that TGFβ induces the expression of the immunoinhibitory molecule Programed death‐ligand 1 (PD‐L1) in human and murine fibroblasts in a Smad2/3‐ and YAP/TAZ‐dependent manner. Furthermore, PD‐L1 knockdown decreased the TGFβ‐dependent induction of extracellular matrix proteins, including collagen Iα1 (colIα1) and alpha‐smooth muscle actin (α‐SMA), and cell migration/wound healing. In addition to an endogenous role for PD‐L1 in profibrotic TGFβ signaling, TGFβ stimulated‐human lung fibroblast‐derived PD‐L1 into extracellular vesicles (EVs) capable of inhibiting T cell proliferation in response to T cell receptor stimulation and mediating fibroblast cell migration. These findings provide new insights and potential targets for a variety of fibrotic and malignant diseases.
Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease
Tariq, Raseen , Disbrow, Molly, DiBaise, John K. , Orenstein, Robert , Saha, Srishti , Solanky, Dipesh , Loftus, Edward V. , Pardi, Darrell S. , Khanna, Sahil , Disbrow, Molly B, Loftus, Edward V , Tariq, Raseen

Mayo Clinic

Inflammatory Bowel Diseases | December 10, 2019 | Volume: 26 | Issue: 9 | Pages: 1415-1420

10.1093/ibd/izz299 | PMID 31821444 Get It

AbstractBackgroundClostridioides difficile infection (CDI) is associated with poor outcomes in inflammatory bowel disease (IBD) patients. Data are scarce on efficacy of fecal microbiota transplant (FMT) for recurrent CDI in IBD patients.MethodsWe reviewed health records of IBD patients (18 years of age or older) with recurrent CDI who underwent FMT. Outcomes of FMT for CDI were assessed on the basis of symptoms and stool test results.ResultsWe included 145 patients (75 women [51.7%]; median age, 46 years). Median IBD duration was 8 (range, 0–47) years, 36.6% had Crohn disease, 61.4% had ulcerative colitis, and 2.1% had indeterminate colitis. Median number of prior CDI episodes was 3 (range, 3–20), and 61.4% had received vancomycin taper. Diarrhea resolved after FMT in 48 patients (33.1%) without further testing. Ninety-five patients (65.5%) underwent CDI testing owing to post-FMT recurrent diarrhea; 29 (20.0%) had positive results. After FMT, 2 patients received empiric treatment of recurrent CDI without symptom resolution, suggesting IBD was the cause of symptoms. The overall cure rate of CDI after FMT was 80.0%, without CDI recurrence at median follow-up of 9.3 (range, 0.1–51) months. Forty-three patients (29.7%) had planned IBD therapy escalation after CDI resolution; none de-escalated or discontinued IBD therapy. Overall, 7.6% had worsening IBD symptoms after FMT that were treated as new IBD flares. No clinical predictors of FMT failure were identified.ConclusionsFew patients had new IBD flare after FMT. Fecal microbiota transplantation effectively treats recurrent CDI in IBD patients but has no apparent beneficial effect on the IBD course.
Nonlinear Z‐score modeling for improved detection of cognitive abnormality
Kornak, John , Fields, Julie A. , Kremers, Walter K. , Farmer, Sara A., Heuer, Hilary W. , Forsberg, Leah K. , Brushaber, Danielle , Rindels, Amy, Weıntraub, Sandra , Besser, Lilah M., Bordelon, Yvette , Bove, Jessica, Brannelly, Patrick , Caso, Christina, Coppola, Giovanni , Dever, Reilly, Dheel, Christina, Dickerson, Bradford, Dickinson, Susan, Domínguez, S. Carbajal, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrall, Jessica, Fishman, Ann, Gavrilova, Ralitza H. , Gearhart, Deb, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiao, John , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kraft, Ruth, Kramer, Joel H. , Kukull, Walter A. , Ljubenkov, Peter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Multani, Namita, Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Len, Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Roberson, Erik D. , Rogalski-Miller, Emily, Sengdy, Pheth, Shaw, Les, Staffaroni, Adam M. , Sutherland, Margaret , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , Farmer, Sara, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Dodge, Hiroko Hayama , Appleby, Brian S. , Fong, Jamie , Foroud, Tatiana , Gearhart, Deb, Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Kerwin, Diana , Knopman, David S. , Lapid, Maria I. , Litvan, Irene , Padmanabhan, Jaya , Toga, Arthur W. , Wang, Ping , Wszołek, Zbigniew K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | December 5, 2019 | Volume: 11 | Issue: 1 | Pages: 797-808

10.1016/j.dadm.2019.08.003 | PMID 31872042 Get It

AbstractIntroductionConventional Z‐scores are generated by subtracting the mean and dividing by the standard deviation. More recent methods linearly correct for age, sex, and education, so that these “adjusted” Z‐scores better represent whether an individual's cognitive performance is abnormal. Extreme negative Z‐scores for individuals relative to this normative distribution are considered indicative of cognitive deficiency.MethodsIn this article, we consider nonlinear shape constrained additive models accounting for age, sex, and education (correcting for nonlinearity). Additional shape constrained additive models account for varying standard deviation of the cognitive scores with age (correcting for heterogeneity of variance).ResultsCorrected Z‐scores based on nonlinear shape constrained additive models provide improved adjustment for age, sex, and education, as indicated by higher adjusted‐R2.DiscussionNonlinearly corrected Z‐scores with respect to age, sex, and education with age‐varying residual standard deviation allow for improved detection of non‐normative extreme cognitive scores.
Psychosis Remitted After Ependymoma Resection in a School-Aged Child
Jules-Dole, Nadimire, Uribe-Cardenas, Rafael , McReynolds, Lisa J. , Borden, Lindsay, Chambers, Shawn, Bell, W. R., Ahn, Edward S. , Bell, W Robert, Raabe, Eric, Salpekar, Jay A, Bell, W. Robert, Raabe, Eric H. , Salpekar, Jay A.

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | December 4, 2019 | Volume: 32 | Issue: 3 | Pages: 305-308

10.1176/appi.neuropsych.19070147 | PMID 31795806 Get It